The Consumer Reports ratings are based on data hospitals reported to the CDC between October 2014 and September 2015. The data is released periodically over the year. Consumer Reports also released C.

Researchers from the University of Virginia in Charlottesville have discovered a type of gut bacteria that could prove effective where other types of helpful bacteria have failed in the fight against ...

A novel vaccination approach developed by Vanderbilt Health researchers cleared the harmful gut bacterium Clostridioides ...

C. diff is a horrible disease that can cause significant morbidity. It can and often does recur and kills around 30,000 Americans every year. We have made progress in prevention and treatment, but ...

The risk of getting a deadly, treatment-resistant infection in a hospital or nursing home is dropping for the first time in decades, thanks to new guidelines on antibiotic use and stricter cleaning ...

Dear Dr. Roach: I have an immunoglobulion A (IgA) deficiency and have had to take many antibiotics over the years. But I have never contracted Clostridioides difficile (C. diff) until I took ...

Nearly half a million people in the United States suffer from an intestinal infection called Clostridium difficile each year. Approximately half of those individuals become sick enough to require ...

Charles Darkoh, Ph.D., a researcher at The University of Texas Health Science Center at Houston (UTHealth) School of Public Health, was recently awarded a five-year, $1.9 million R01 grant by the ...

The big breakthrough in C. diff treatment was reported by the New England Journal of Medicine in 2013. Researchers in the Netherlands conducted a randomized controlled trial comparing the ...

Clostridioides difficile/Clostridium difficile (C. diff) is a bacterial infection and is the most common cause of healthcare-associated diarrhea. C. diff has two distinct presentations, primary and ...

There are inherent risks in biotech investing. A decade’s worth and often hundreds of millions of dollars in R&D, along with binary risks of failed clinical trials or regulatory approval. Above and ...